Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung…
By L. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh, M. Krzakowski, M. Pawlicki, P. Souza, M. Zheng, G. Urbanowitz and 2 more. Journal of Clinical Oncology, 2003
712 citations recorded by the source corpus.
Subfields: Oncology, Radiology, Nuclear Medicine and Imaging, Surgery
View Paper: https://www.semanticscholar.org/paper/f0f96cbeb2e7a86ddb092a6a8a579eb514fe9aa1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
Citations in the corpus
- Pathologic fractures correlate with reduced survival in patients with malignant bone disease (2007, methodology): “MATERIALS AND METHODS Patients and Study Design This was a retrospective analysis of 3 randomized, double-blind, controlled phase 3 trials of zoledronic acid in adult patients with bone metastases/lesions from stage IV breast cancer or Durie-Salmon stage III multiple myeloma,(15,19) hormone-refracto”
- Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma (2003, background): “acid has demonstrated superiority over pamidronate in the treatment of HCM(19) and is the first bisphosphonate to demonstrate efficacy in patients with bone metastases from solid tumors other than breast carcinoma, including prostate carcinoma, nonsmall cell lung carcinoma, and a variety of other tu”
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. (2012, background): “Effective measures at preventing skeletal-related events such as biphosphonates [23, 24] or prophylactive radiotherapy [25] may help in reducing the rates of adverse outcomes.”